Related Experiment Video
Updated: Jun 25, 2026

Modifying Levels of Maternal Dietary Folic Acid or Choline to Study the Impact of Deficiencies on Offspring Health Outcomes
Published on: June 28, 2024
Cerebral folate deficiency
1neil-gordon@doctors.org.uk
Insights
Cerebral folate deficiency (CFD) causes developmental delays in infants due to low brain folate. Treatment with folinic acid can significantly improve symptoms and restore folate levels.
Area of Science:
- Neurology
- Pediatrics
- Biochemistry
Background:
- Cerebral folate deficiency (CFD) is characterized by low 5-methyltetrahydrofolate in cerebrospinal fluid (CSF) despite normal plasma folate levels.
- Symptoms manifest around 4-6 months of age, including developmental delay, hypotonia, ataxia, and potentially dyskinesias, spasticity, speech issues, and epilepsy.
Purpose of the Study:
- To investigate the cause and treatment of cerebral folate deficiency.
- To explore the role of folate transport across the blood-brain barrier and the potential impact of folate receptor antibodies.
- To evaluate the efficacy of folinic acid treatment and its implications for diagnosing neurological disorders.
Main Methods:
- Analysis of folate levels in CSF, plasma, and red blood cells.
- Clinical observation of developmental milestones and neurological symptoms.
- Assessment of treatment response to folinic acid therapy.
Main Results:
- Low CSF 5-methyltetrahydrofolate levels are linked to impaired folate transport into the brain, possibly due to antibody blockade of folate receptors.
- Prolonged folinic acid treatment led to significant clinical improvement and normalization of CSF 5-methyltetrahydrofolate levels.
- CFD is a treatable condition with a positive response to folinic acid.
Conclusions:
- Cerebral folate deficiency is a treatable cause of neurological impairment in infants.
- Screening CSF for folate levels in patients with unexplained neurological disorders is warranted.
- Understanding folate transport mechanisms is crucial for diagnosing and managing CFD.
Abstract:
Cerebral folate deficiency (CFD) is associated with low levels of 5-methyltetrahydrofolate in the cerebrospinal fluid (CSF) with normal folate levels in the plasma and red blood cells. The onset of symptoms caused by the deficiency of folates in the brain is at around 4 to 6 months of age. This is followed by delayed development, with deceleration of head growth, hypotonia, and ataxia, followed in one-third of children by dyskinesias (choreo-athetosis, hemiballismus), spasticity, speech difficulties, and epilepsy. The low level of 5-methyltetrahydrofolate in the CSF can result from decreased transport across the blood-brain barrier, which is most probably because of the blocking of folate transport into the CSF by the binding of folate receptor antibodies to the folate receptors in the choroid plexus. Treatment of the condition with folinic acid for prolonged periods can result in significant improvement of clinical symptoms and a return of 5-methyltetrahydrofolate levels in the CSF to normal. In view of this response to treatment in CFD and allied conditions, a case can be made for screening the CSF of patients with neurological disorders of unknown origin.
More Related Videos
Related Concept Videos
Vitamins
Cerebral Edema ll: Pathophysiology
Hepatic Encephalopathy
Cerebral Edema l: Introduction
Cryptococcal Meningitis
Encephalitis l: Introduction

